Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic haematopoietic cells in cancer: From biology to therapy by Döme, Balázs et al.
C1
2
3
4
5
6
7
T
1
dCritical Reviews in Oncology/Hematology 69 (2009) 108–124
Circulating endothelial cells, bone marrow-derived endothelial
progenitor cells and proangiogenic hematopoietic cells in cancer:
From biology to therapy
Balazs Dome a,b,∗, Jozsef Timar c, Andrea Ladanyi c, Sandor Paku d, Ferenc Renyi-Vamos a,
Walter Klepetko e, Gyorgy Lang e, Peter Dome f, Krisztina Bogos a,b, Jozsef Tovari a,c
a Department of Tumor Biology, National Koranyi Institute of Pulmonology, Piheno u. 1, Budapest H-1529, Hungary
b Department of Thoracic Oncology, National Koranyi Institute of Pulmonology, Budapest, Hungary
c Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary
d First Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
e Department of Cardio-Thoracic Surgery, Medical University of Vienna, Vienna, Austria
f Department of Clinical and Theoretical Mental Health, Kutvolgyi Clinical Center, Semmelweis University, Budapest, Hungary
Accepted 26 June 2008
ontents
. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
. Circulating endothelial cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
2.1. Characterization and enumeration of circulating endothelial cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
2.2. Circulating endothelial cells in human malignancies (Table 2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
. Endothelial progenitor cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
3.1. Characterization and enumeration of endothelial progenitor cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
3.2. Regulation of endothelial progenitor cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
ig. 1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1143.3. Endothelial progenitor cells in animal tumor models (F
3.4. Endothelial progenitor cells in human tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
. Proangiogenic hematopoietic cells (Fig. 1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
. Antiangiogenic and/or anticancer therapy via EPCs, proangiogenic HCs and CECs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
. EPCs and CECs: potential biomarkers of tumor angiogenesis? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Reviewers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Abbreviations: SMA, -smooth muscle actin; AML, acute myeloid leukemia; Ang-1, angiopoietin-1; BM, bone marrow; CAC, circulating angiogenic
cell; CEC, circulating endothelial cell; CFU-EC, colony-forming unit-endothelial cells; CLL, chronic lymphocytic leukemia; CRP, C-reactive protein; CSF-1R,
colony-stimulating factor-1 receptor; CT, computed tomography; DC, dendritic cell; EC, endothelial cell; ECFC, endothelial colony-forming cell; EPC, endothe-
lial progenitor cell; EPOR, erythropoietin receptor; FGFR, fibroblast growth factor receptor; FISH, fluorescent in situ hybridization; FLT-3, FMS-like tyrosine
kinase 3; FSC, forward scatter; GFP, green fluorescent protein; GIST, gastrointestinal stromal tumor; GM-CSF, granulocyte-macrophage colony-stimulating
factor; HC, hematopoietic cell; HIF-1, hypoxia-inducible factor-1; HSV-TK, herpes simplex virus thymidine kinase; IFN, interferon; IMS, immunomagnetic
separation; MC, mast cell; MDSC, myeloid-derived suppressor cell; MMP, matrix metalloprotease; MNC, mononuclear cell; MRI, magnetic resonance imag-
ing; MTD chemotherapy, maximum tolerable dose chemotherapy; NO, nitric oxide; PB, peripheral blood; PDGF-CC, platelet-derived growth factor-CC; PET,
positron emission tomography; PlGF, placental growth factor; PMN, polymorphonuclear cell; RBCC, recruited blood circulating cell; rHuEPO, recombinant
human erythropoietin; SDF-1, stromal cell-derived factor-1; SPECT, single photon emission computed tomography; SSC, side scatter; TAM, tumor-associated
macrophage; TASC, tumor-associated stromal cell; TEM, TIE2-expressing monocyte; TGF-, transforming growth factor-; Tie-2/TEK, angiopoietin-1 recep-
tor precursor or tunica intima EC kinase; TNF-, tumor necrosis factor-alpha; TSP-1, thrombospondin-1; tsVEGFR2, truncated soluble VEGFR2; UEA-1,
Ulex Europaeus lectin-1; VDA, vascular disrupting agent; VE-cadherin, vascular endothelial cadherin; VEGFR, vascular endothelial growth factor receptor;
vWf, von Willebrand factor.∗ Corresponding author at: Department of Tumor Biology, National Koranyi Institute of Pulmonology, Piheno u. 1, Budapest H-1529, Hungary.
el.: +36 1 391 3210; fax: +36 1 391 3223.
E-mail address: domeb@yahoo.com (B. Dome) .
040-8428/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.critrevonc.2008.06.009
AH
s
fi
E
t
a
p
©
K
1
e
p
c
i
o
w
s
t
i
c
i
d
o
h
i
h
a
v
i
t
c
a
e
e
s
l
“
(
v
b
o
o
wB. Dome et al. / Critical Reviews in Oncology/Hematology 69 (2009) 108–124 109
Conflicts of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Biographies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
bstract
Vascularization, a hallmark of tumorigenesis, is classically thought to occur exclusively through angiogenesis (i.e. endothelial sprouting).
owever, there is a growing body of evidence that endothelial progenitor cells (EPCs) and proangiogenic hematopoietic cells (HCs) are able to
upport the vascularization of tumors and may therefore play a synergistic role with angiogenesis. An additional cell type being studied in the
eld of tumor vascularization is the circulating endothelial cell (CEC), whose presence in elevated numbers reflects vascular injury. Levels of
PCs and CECs are reported to correlate with tumor stage and have been evaluated as biomarkers of the efficacy of anticancer/antiangiogenic
reatments. Furthermore, because EPCs and subtypes of proangiogenic HCs are actively participating in capillary growth, these cells are
ttractive potential vehicles for delivering therapeutic molecules. The current paper provides an update on the biology of CECs, EPCs and
roangiogenic HCs, and explores the utility of these cell populations for clinical oncology.
2008 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
It has been over 30 years since Judah Folkman hypoth-
sized that neovasculature plays a significant role in tumor
rogression and might well be an optimal target for anti-
ancer strategies [1]. Subsequent research has led to the
dentification of several regulators of angiogenesis, some
f which represent therapeutic targets. However, it is also
ell established now that tumor vasculature does not neces-
arily derive from endothelial cell (EC) sprouting; instead,
umors can acquire their vasculature by various mechanisms
ncluding postnatal vasculogenesis, a process during which
irculating bone marrow (BM)-derived endothelial progen-
tor cells (EPCs) home to sites of neovascularization and
ifferentiate into ECs [2]. EPCs therefore resemble embry-
nic angioblasts, which are anchorage-independent cells
aving the capacity to proliferate, migrate and differentiate
nto mature ECs. Since the first description of EPCs by Asa-
ara et al. [3], several authors have found decreased numbers
nd/or impaired function of EPCs in a variety of cardio-
ascular diseases. In contrast, blood levels of EPCs tend to
ncrease in cancer patients and to correlate with the stage of
he malignant disease [4].
Infiltration of human tumors by certain types of leuko-
ytes, like lymphocytes and dendritic cells (DCs) is often
ssociated with better prognosis and overall survival. How-
ver, other leukocyte subsets such as macrophages can
nhance tumor angiogenesis and progression [5]. Moreover,
everal studies on experimental tumor models have been pub-
ished suggesting that even before the onset of the so called
angiogenic switch” [6], various types of hematopoietic cells
HCs) are recruited to the tumor tissue to enhance new blood
essel formation by secreting angiogenic molecules and/or
y trans-differentiation into endothelial-like cells [7]. These
bservations have led to the concept that certain populations
f HCs are proangiogenic and co-mobilized from the BM
ith EPCs [8].
M
i
t
i
sating endothelial cells; Vasculogenesis; Angiogenesis; Cancer
Another related cell type is the circulating endothelial cell
CEC). These cells are thought to be mature ECs that have
etached from their basement membrane in response to some
orm of blood vessel injury. Accordingly, increased num-
ers of CECs, rare in healthy individuals, are observed in
broad range of conditions/diseases associated with vascu-
ar perturbation, including tumor-induced neovascularization
9]. Therefore, although their biology is still obscure, there is
growing belief that together with EPCs, CECs may evolve
nto a surrogate biomarker for monitoring tumor angiogenesis
nd the efficacy of anticancer/antiangiogenic therapies.
This review starts with a summary on the phenotype, enu-
eration strategies and clinical significance of CECs. We
hen discuss the characterization of EPCs and proangiogenic
Cs, as well as the molecules that regulate their release from
he BM and their homing to or incorporation into neovas-
ular networks. Finally, we review the potential therapeutic
nd diagnostic implications of EPCs and HCs in medical
ncology.
. Circulating endothelial cells
Although CECs were first described over 30 years
go through methods such as vital light microscopy,
ay–Grünwald–Giemsa staining and separation by Ficoll
ensity centrifugation [10,11], the development of specific
onoclonal antibodies has only recently provided an oppor-
unity to investigate the pathophysiology of these cells. In
991, monoclonal antibodies to two novel EC specific sur-
ace antigens (HEC19 [12] and S-Endo-1 [13], later described
s CD146 [14]) were developed and used to quantify CECs.
ore recently, these authors and others have used themmunobead technique and/or flow cytometry to investigate
he significance of CECs in a variety of diseases including
nfections, cardiovascular, inflammatory and autoimmune
yndromes and cancer (reviewed in ref. [9]).
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.1. Characterization and enumeration of circulating
ndothelial cells
In practice, the main problem in clinical studies with the
uantification of CECs is their low frequency in the peripheral
lood (PB). To quantify these rare cells, different tech-
iques of cell enrichment together with immunocytochemical
etection have been applied, such as density centrifugation
ethods, cell culture and immunomagnetic separation (IMS).
he latter technique, developed by George et al., includes
ixing PB with immunomagnetic beads coated with anti-
D146 antibodies, which then bind to CD146-expressing
ECs and are selected by magnet retrieval [15]. However,
lthough it is most frequently used for CEC enumeration,
D146 expression has also been reported in pericytes, bone
arrow fibroblasts, cancer cells, trophoblasts, and activated
ymphocytes; thus, caution in interpreting results with CD146
lone is advised [16,17]. Nevertheless, unspecific CD146
xpression should not necessarily considered as a techni-
al limitation in the detection of CECs, since CD146-based
MS has been adapted to cope with it. IMS is best accom-
anied by an additional specific characterization step, such
s Ulex Europaeus lectin-1 (UEA-1), CD31 or von Wille-
rand factor (vWf) labeling to confirm that all sorted cells
re CECs. This methodology has been used successfully in a
arge number of studies showing altered CEC levels in vari-
us diseases. Accordingly, the authors of a recent multicentric
tudy defined CECs as cells that exceed 10m in size and
ave more than five immunomagnetic beads attached. The
osetted cells stain positive with at least two EC markers (for
xample, CD146 and UEA-1) and are negative for leukocyte
arkers (for example, CD14 and CD45, Table 1) [18].
A widespread alternative to the IMS technique is flow
ytometry, during which whole PB is usually labeled with
ndothelial-specific antibodies conjugated with different
uorochromes. An advantage of flow cytometry is rapid
ultiparametric analysis and the ability to detect sub-
opulations, such as “bright” versus “dim” labeling, and
ctivated (e.g. expressing CD106) or resting, although CECs
eparated by the IMS method can also be multiply labeled.
or example, Duda et al. recently reported a cytometry proto-
ol for phenotypic identification and quantification of CECs
n human PB. Using four surface markers (CD31, CD34,
D133 and CD45) and multicolor flow cytometry, their group
as proposed a surface phenotype of viable CECs (defined
s CD31brightCD34+CD45−CD133− cells) [19]. However,
here are substantial differences between IMS and flow cyto-
etric techniques, as indicated by the high variation in
eported CEC numbers. On the basis of CD31bright/CD45−
taining, the amount of cells recorded per milliliter of PB
s about 1000- to 100,000-fold higher than the number of
ECs reported in healthy controls and in different categories
f patients using CD146-based IMS. The recent results of
trijbos et al. [20] may, in part, explain the significantly
igher CD146+ CEC levels as reported using the single-
latform flow cytometric assay and those determined by
p
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D146-based IMS techniques. In their study, these authors
ocused on confirming the widely used single-platform flow
ytometric assay for CECs, as per the method of Man-
uso et al. [21], using their previously reported CEC profile
forward scatter (FSC)low-to-intermediate, side scatter (SSC)low,
D31bright/CD146+/CD45−]. Interestingly, by using reverse
ranscription polymerase chain reaction, electron microscopy
nd fluorescence in situ hybridization (FISH), Strijbos et al.
emonstrated that cells with the above phenotype are in fact
ot CECs but large platelets [20].
In light of these results, CEC enumeration is far from being
standardized procedure and the confusion in CEC num-
ers does raise serious questions concerning the reliability of
he above techniques. Because there are no studies currently
vailable demonstrating the superiority of one technique over
he other, more research is required to measure/correlate the
ccuracy of the above methods.
.2. Circulating endothelial cells in human
alignancies (Table 2)
Elevated levels of CECs have been repeatedly found in
ifferent types of human malignancies. This observation first
ppeared in the literature in 2001 when Mancuso et al.,
sing 4-color flow cytometry, found that in breast cancer and
ymphoma patients, both resting and activated CECs were
ncreased significantly [21]. In addition, CEC levels were
imilar to healthy controls in lymphoma patients achieving
omplete remission after chemotherapy, and activated CECs
ere found to decrease in breast cancer patients evaluated
fter surgery. Although they employed different methods of
ssessing CEC levels and disease stage, Beerepoot et al. also
eported a significant CEC elevation in cancer patients with
rogressive disease, whereas their patients with stable disease
ad CEC levels comparable to those of healthy individuals
22].
Subsequent studies yielded similar results. Zhang et
l. investigated CECs in multiple myeloma, demonstrating
ncreased numbers of these cells (P < 0.001 vs. healthy con-
rols) [23]. Wierzbowska et al. evaluated CEC levels by
-color flow cytometry in acute myeloid leukemia (AML) and
eported elevated numbers of both resting and activated CECs
24]. In their study, CEC levels were correlated with disease
tatus and response to treatment as well. In another study
n breast cancer, CECs were found to be significantly ele-
ated in cancer patients and decreased during chemotherapy
25]. More recently, Rowand et al. observed that CEC counts
ere significantly higher in metastatic carcinoma patients
ompared to healthy controls [26]. Similarly, increased CEC
evels have been reported in the PB of patients with gastroin-
estinal stromal tumor (GIST) [27], myelodysplastic syn-
rome [28] and chronic lymphocytic leukemia (CLL) [29].Taken together, it is apparent that CECs are increased in
atients with different types of malignancies. Furthermore,
here is a growing body of evidence that this cell population
ay evolve into a surrogate biomarker for measuring the
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Table 1
CECs, EPCs and proangiogenic HCs in cancer
Cell type Source Morphology/phenotype/molecular
profile
Role/significance in
tumor vascularization
Proliferative potential Ref.
CEC Blood vessel wall Mature circulating
cells < 50m in diameter;
CD146, CD31, CD34, vWf,
VE-cadherin, UEA-1, acLDL
Biomarker of endothelial
injury, angiogenesis
and/or the efficacy of
anticancer
(antiangiogenic) therapy
No [16–19]
EPC BM Immature circulating cells
∼20m in diameter; CD133,
CD34, VEGFR2, CD38,
c-kit, CD31, CXCR4
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [33,43]
CFU-EC Culture PBMNCs growing in
colonies for ∼7 days
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [39]
CAC Culture PBMNCs growing in the
presence of angiogenic
cytokines for ∼4–6 days
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [40]
ECFC Culture PBMNCs growing in
cobblestone patterned
colonies for ∼21 days
Support of tumor
vascularization/biomarker
of endothelial injury,
angiogenesis and/or the
efficacy of anticancer
(antiangiogenic)
therapy/vehicle for drug
delivery
Yes [42]
TEM BM CD11b, CD45, TIE2 Support of tumor
vascularization
Yes [68]
DC BM
MHC II+/CD11c+
conventional/myeloid DCs
Support of tumor
vascularization
[119]
CD123+/CD303+
plasmacytoid DCs
Support of tumor
vascularization
[119]
CD11c+/CCR6+/MHC II+
TADCs
Support of tumor
vascularization
Yes [120,121]
MDSC BM CD11b, Gr-1 Support of tumor
vascularization
Yes [100,106]
TASC BM CD45, VEGFR2 Support of tumor
vascularization
Yes [122]
RBCC BM CD45, CD11b, CXCR4,
VEGFR1
Support of tumor
vascularization
Yes [123]
VEGFR1+ HC BM VEGFR1, VLA-4 Support of tumor
vascularization/initiation
of the pre-metastatic
niche
Yes [124]
BM, bone marrow; CAC, circulating angiogenic cell; CEC, circulating endothelial cell; CFU-EC, colony-forming unit-endothelial cells; DC, dendritic cell;
ECFC, endothelial colony-forming cell; EPC, endothelial progenitor cell; MDSC, myeloid-derived suppressor cells; PBMNC, peripheral blood mononuclear
cell; RBCC, recruited blood circulating cell; TADC, tumor-associated dendritic cell; TASC, tumor-associated stromal cell; TEM, TIE2-expressing monocyte;
VEGFR1, vascular endothelial growth factor receptor-1.
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Table 2
Levels of CECs and EPCs in patients with malignant diseases
Tumor type Number
of cases
Enumeration Phenotype Mean CEC levels (patients
vs. controls, n/mL of PB)
Mean EPC levels (patients vs.
controls, n/mL of PB)
Ref.
CEC EPC
Breast cancer, lymphoma 76 FC CD45−/CD146+/CD31+/CD34+ CD45−/CD31+/CD133+ 39,100 vs. 7900 Below 500 both in patients
and controls
[2]
Variousa 95 CD146-IMS CD146+/CD31+/vWF+/VEGFR2+ NA 438 vs. 121b NA [22]
Multiple myeloma 31 FC + culture CD34+/CD146+/CD105+/CD11b− CFU-ECs CFU score ∼6-fold higher in
patientsc
NA [23]
AML 48 FC CD45−/CD31+/CD34+CD146+ CD45−/CD31+/CD34+CD133+ 36,700 vs. 3200 700 vs. 100 [24]
Myelofibrosis 110 FC NA CD133+/CD34+/VEGFR2+ NA 165 vs. 0 [88]
CLL 20 FC CD45−/CD31+/CD146+ NA 26.5 vs. 18.5 NA [29]
MDS 128 FC CD45−/CD34+/CD146+/CD133− NA 512 vs. 153 NA [28]
Breast cancer 16 FC CD45−/CD146+/CD31+/CD34+ CD34+/VEGFR2+ 5700 vs. 1300 370 vs. 140 [25]
Breast cancer 47 FC NA CD34+/VEGFR2+ NA 0.44 vs. 0.18d [84]
Breast cancer 25 FC NA CD133+/VEGFR2+ NA 0.032 vs. 0.023d,e [85]
Gastric/breast cancer 71 Culture NA CFU-ECs NA 40.2 vs. 37.6 (n.s.)f [155]
Lung cancer 53 FC NA CD34+/VEGFR2+ NA 1162 vs. 345 [80]
Lung cancer 10 FC CD34-IMS
Cytospin
NA CD45−/CD34+/VEGFR2+ and
CD45−/CD133+/VEGFR2+
NA 90 vs. 42 and 0.3 vs. 0.1g [83]
Liver cancer 80 Culture NA CFU-ECs NA CFU score 10-fold higher in
patients
[46]
Liver cancer 64 Culture NA CFU-ECs NA CFU score ∼2-fold higher in
patients
[79]
Glioma 32 FC CD34+/CD146+/VEGFR2− CD133+/CD34+/VEGFR2+ n.s. 0.18 vs. 0.01d [89]
Varioush 206 IMS CD45−/CD146+/CD105+ NA 111 vs. 21 NA [26]
Variousi 44 FC CD45−/CD34+/CD133−/CD105− CD45−/CD34+/CD133+/CD105− 470 vs. 140 (n.s.) 90 vs. 30 (n.s.) [154]
GIST 16 FC CD45−/CD31+/P1H12+/CD133− NA 1090 vs. 540 NA [27]
CEC, circulating endothelial cell; CLL, chronic lymphocytic leukemia; CFU-ECs, colony-forming unit-endothelial cells; EPC, endothelial progenitor cell; FC, flow cytometry; GIST, gastrointestinal stromal
tumor; IMS, immunomagnetic separation; MDS, myelodysplastic syndrome; n.s., non-significant; PB, peripheral blood.
a Different cancer patients with progressive disease. Tumor types included head and neck (10 patients), colon (13 patients), prostate (25 patients), gastric (3 patients), esophagus (3 patients), renal cell (6
patients), breast (10 patients), ovarian (5 patients), cervical cancer (2 patients), carcinoid (3 patients), melanoma (3 patients), glioma (2 patients), and 10 patients with other tumor types.
b Patients with stable disease had CEC numbers equal to that circulating in healthy subjects (P = 0.69).
c Raw data not supplied.
d % of PB mononuclear cells.
e Stage III vs. stage IV patients.
f Stated per unit area (mm2).
g % of CD34 enriched cells.
h 50 cases of breast cancer, 49 of colorectal cancer, 35 of lung cancer, 48 of prostate cancer, and a group of other carcinomas consisting of 8 ovarian/pancreatic, 3 renal, 2 bladder, 2 thyroid, 2 gastric, and 1
breast/colon, colon/prostate, esophageal, gastric, carcinoid tumor, squamous cell, tongue, and mandibular cancer.
i Patients with different refractory solid malignancies pretreated with chemotherapy. Details of the patient population not supplied.
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ffectiveness of conventional and targeted (antiangiogenic)
nticancer therapy. What is less clear is whether or not CECs
re simply biomarkers of the accelerated endothelial turnover
f tumor capillaries, or are active participants of tumor pro-
ression and vascularization. However, it is also possible that
ECs are not being desquamated from activated tumor vas-
ulature. Instead, their increased number in the PB may be
he result of a more generalized systemic (i.e. paraneoplastic)
ndothelial damage and/or activation.
. Endothelial progenitor cells
.1. Characterization and enumeration of endothelial
rogenitor cells
EPCs were discovered and identified in 1997 by Asahara
t al. [3] on the basis of vascular endothelial growth fac-
or receptor-2 (VEGFR2) and CD34 co-expression. Since
hen, the emergence of specific membrane markers and
olecular probes has facilitated the identification and purifi-
ation of functional stem and progenitor cells. A number of
esearchers have set out to better characterize these cells,
nd EPCs were subsequently shown to express fibroblast
rowth factor receptor (FGFR), CD38, c-kit, CD31, CXCR4,
Wf, vascular endothelial cadherin (VE-cadherin), Tie-
/TEK (angiopoietin-1 receptor precursor or tunica intima
C kinase) and CD133 [30–33]. However, it is still extremely
ifficult to differentiate EPCs from HCs or CECs, since the
arkers used to separate EPCs are expressed on subsets of
Cs (CD34, VEGFR2, CD133, VE-cadherin) and mature
Cs/CECs (CD34, VE-cadherin) as well. In fact, the pop-
lation of EPCs may include a group of cells existing in a
ariety of stages ranging from immature HSCs to completely
ifferentiated ECs.
Although to date no clear phenotype of EPCs exists and
heir putative precursors and the exact differentiation lineage
emain to be determined, at present it is widely accepted that
arly EPCs (localized in the BM or immediately after migra-
ion into the bloodstream) are CD133+/CD34+/VEGFR2+
ells, whereas circulating EPCs are positive for CD34 and
EGFR2, lose CD133 and begin to express membrane
olecules typical to mature ECs [2]. Thus, the major can-
idate for a specific circulating EPC marker is the CD133,
n orphan receptor specifically expressed on early EPCs, but
hose expression is lost once these progenitors differenti-
te into mature ECs [34]. Unfortunately, because in humans
D133 is expressed by HSCs as well [35], the techniques for
henotypic differentiation between vasculogenic-restricted
mmature EPCs, committed HSCs and their putative com-
on precursor (bi-potential hemangioblast) have yet to be
eveloped further.Results on PB EPC levels in the bloodstream are vari-
ble, ranging from 70 to 210 cells/mL of PB [36] to
000–5000 cells/mL of PB [37], depending most likely on
he isolation technique used. These relatively low numbers
m
a
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f circulating EPCs as measured by flow cytometry are in
harp contrast to the high numbers of adherent cells (often
onfusingly defined as “EPCs” too) that are observed in PB
ononuclear cell cultures (∼105 from 1 mL blood) (Table 1).
n general, three different methods for culturing “EPCs” have
een reported [38]. In the original approach, in which the
dentification of EPCs is based on their clonogenic and pro-
iferative potential, PB mononuclear cells (MNCs) are plated
n fibronectin-, gelatin- or collagen-coated dishes. Discrete
olonies appear in a week, containing round cells centrally
nd spindle-shaped cells peripherally. The cells of these
olonies are usually referred to as colony-forming unit-ECs
CFU-ECs) [39]. In the second method, MNC cultures are
reated with angiogenic cytokines for 4–6 days, whereupon
on-adherent cells are discarded, resulting in a target adherent
ell population [40]. Because these adherent cells have been
eported to enhance angiogenesis in vivo [41], they have been
efined as circulating angiogenic cells (CACs). Although
ACs do not form colonies and are observed in cultures
n larger numbers than CFU-ECs, they express endothelial
arkers such as CD31, vWF, VE-cadherin and Tie-2/TEK,
ind Bandeiraea simplicifolia (BS-1) and UEA-1 lectins, and
ave the potential to take-up acetylated low-density lipropro-
ein/acLDL. Therefore, CACs appear analogous to CFU-ECs
n surface molecular profile and in vitro properties. The third
nd least known type of “EPC” is now defined as “endothe-
ial colony-forming cell” (ECFC). In this method, MNCs
re growing in the presence of endothelial-specific growth
actors. After removal of non-adherent cells, ECFC colonies
isplaying cobblestone pattern typical of ECs emerge from
he adherent cell population. Because ECFCs emerge much
ater in culture than CFU-ECs or CACs, they have also been
ermed “late outgrowth EPCs” [42].
.2. Regulation of endothelial progenitor cells
In order for EPCs to facilitate the growth of tumor cap-
llaries, they must respond to signals released from the BM,
ome to the tumor site, and differentiate into mature ECs.
lthough the exact molecular background of EPC mobiliza-
ion remains vague, VEGF is thought to be the key cytokine
n the regulation of EPC mobilization and homing [43]. In
nimal models, VEGF through interaction with its receptors,
EGFR2 and VEGFR1 expressed on EPCs and HSCs [44],
ffectively induces the mobilization of these cell populations
nto the circulation; EPC levels in the PB rise within 24 h fol-
owing exogenous VEGF administration [45]. Accordingly,
he increased circulating VEGF level triggers the release of
PCs from the BM of cancer patients [25,46].
Cytokines that induce the release of white and red blood
ells may also trigger EPC mobilization. Elevated levels
f EPCs were reported in mice subsequent to granulocyte-
acrophage colony-stimulating factor (GM-CSF) treatment,
nd accelerated corneal angiogenesis with BM-derived cells
as found in animals treated with GM-CSF [47]. In another
nimal model, granulocyte colony-stimulating factor (G-
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SF) markedly enhanced growth of a colorectal carcinoma
ell line, in part mediated by EPCs incorporated into sites of
ctive blood vessel growth, whereas it had no effect on can-
er cell proliferation in vitro [48]. Similarly, administration of
ecombinant human erythropoietin (rHuEPO) increased both
he level of functionally active EPCs by differentiation in vitro
n a dose-dependent manner and also the number of function-
lly active EPCs in human PB [49]. In addition, serum levels
f EPO were found to be significantly associated with the
umber and function of circulating EPCs [50]. Interestingly,
lthough EPO has a similar potency for the stimulation of
PC mobilization as VEGF [51] and it is widely used for
orrection of hemoglobin level by increasing the number of
ed blood cells, there is no data on the effect of rHuEPO
n EPC mobilization and recruitment when it is delivered
o tumor-bearing animals or cancer patients. However, in
ddition to the potential effects of rHuEPO on cancer cell
roliferation, the expression of EPO receptor (EPOR) in ECs
nd their progenitors raises the possibility that exogenous
HuEPO may enhance the processes of angio- and/or vascu-
ogenesis in tumors (reviewed in ref. [52]). Nevertheless, as
t has been suggested by recent studies, the overall direct
ffect of EPO-EPOR signaling on tumor progression and
herapy is not a straightforward one. For instance, rHuEPO
dministration has recently been shown to be associated with
ecreased intratumoral hypoxia-inducible factor-1 (HIF-
) and VEGF expression and increased sensitivity to radio-
nd chemotherapy of human tumor xenografts [53,54].
In addition to the above molecules, recent results indi-
ate that PlGF (placental growth factor) [55], Ang-1
angiopoietin-1) [56], PDGF-CC (platelet-derived growth
actor-CC) [57], SDF-1 (stromal cell-derived factor-1)
58], NO (nitric oxide) [59], 3-hydroxy-3-methylglutaryl
oenzyme-A reductase inhibitors (statins) [60], estrogens
61] and physical training [62] enhance EPC mobilization as
ell. In contrast, tumor necrosis factor-alpha (TNF-) and
-reactive protein (CRP) promote apoptosis, attenuate the
unction and decrease the level of EPCs [63,64].
.3. Endothelial progenitor cells in animal tumor
odels (Fig. 1)
The observation that EPCs are capable of enhancing tumor
ascularization means that although these progenitor cells
re primarily programmed to support embryogenic vascu-
ogenesis, they retain this capability within an angiogenic
ilieu in the adult. But what evidence is there that EPCs
ctually support new blood vessel growth in tumors? The first
eport on the role of EPCs in tumor-induced vasculogenesis
ates back to 2001, when Lyden et al. [65] demonstrated that
PCs contribute about 90% to vascularization in lymphomas
rown in angiogenesis-defective Id-mutant mice in which
mplanted tumors rapidly regress, most probably because of
he weak angiogenic potential of these animals. BM trans-
lantation from wild-type mice, not from Id-mutant mice,
estored the tumor neovascularization and growth in Id-
t
o
t
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utant mice. However, the high contribution of EPCs in
he neovessels of this tumor model almost certainly results
rom the fact that recipient Id-deficient mice are angiogenic-
eficient as well, and therefore compensatory mechanisms
such as tumor-induced vasculogenesis) are activated to sus-
ain tumor growth. In subsequent animal transplantation
odels, EPCs incorporated into neovessels, sometimes by as
uch as 50% [66], whereas other authors reported lower but
ignificant levels between 10% and 20% [67]. These reports
ave been challenged by some other experiments in which
PCs had no significant contribution to the tumor vasculature.
or example, De Palma et al. [68] found that TIE2-expressing
onocytes (TEMs), rather than EPCs, homed to tumors and
nteracted with vascular ECs. Interestingly, these authors did
ot observe EPCs in the tumor vasculature. Similarly, based
n their observations in a transgenic mouse model, Gothert et
l. failed to observe EPCs in tumor capillaries [69]. Although
ossible reasons for such inconsistent results might include
he use of differing experimental models/techniques to iden-
ify EPCs, recent data suggest that the involvement of EPCs in
xperimental tumor vascularization might also vary depend-
ng on tumor stage and/or grade. Using different mouse
odels, a German group reported recently that only advanced
umors recruit and incorporate EPCs into neovessels, possibly
o further compensate for escalating blood supply require-
ents [70]. Along this line, Ruzinova et al. found that the
ontribution of EPCs to the tumor vasculature depends on
he tumor grade, since EPCs distinguished between well- and
oorly differentiated carcinoma cell lines [71]. Finally, vari-
tions in EPC levels and their involvement in the actual phase
f tumor growth might also be caused by chemotherapy.
he evidence for this assumption comes from another animal
tudy in which mice were treated with the maximum tolera-
le dose (MTD) versus metronomic (i.e. antiangiogenic [72])
hemotherapy. Surprisingly, while animals treated with the
TD chemotherapy experienced a robust EPC mobilization
few days after the end of a cycle of drug administration, the
dministration of metronomic chemotherapy was associated
ith a consistent decrease in EPC levels [73].
In addition to the physical contribution of EPCs to newly
ormed capillaries, the angiogenic cytokine release of EPCs
ay be a supportive mechanism to improve neovasculariza-
ion as well [74]. This idea is supported by a recent report by
ao et al. [75]. These authors found that although only 12% of
he new blood vessels showed incorporation of EPCs, block-
ng EPC mobilization caused severe angiogenesis inhibition
nd significantly impaired tumor progression. Moreover, in
he same study, gene expression analysis of EPCs revealed
p-regulation of a variety of key proangiogenic genes.
In conclusion, EPCs seem to have both paracrine and
tructural roles in new vessel growth. However, although
PCs are obviously able to support tumor vascularization,he involvement of this cell population may vary depending
n circumstances such as the experimental model or detec-
ion method used, the histology and stage of the tumor, and
he type of the anticancer treatment.
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Fig. 1. Schematic representation of the roles of CECs, EPCs and HCs in cancer. CECs represent a population of mature ECs that have desquamated from their
basal membrane into the circulation in response to some form of blood vessel injury [16]. CEC levels are elevated in patients with different types of malignancies
and in various other conditions including ischemic, infective, autoimmune and inflammatory diseases [17]. EPCs are circulating, BM-derived cells that appear
to enhance neovascularization in both physiologic and pathologic settings. These cells have been found in decreased numbers and/or with impaired function in
a variety of cardiovascular diseases. In contrast, circulating levels of EPCs tend to increase in cancer patients and to correlate with the stage of the malignant
disease [43]. In addition to EPCs, tumor vascularization and growth might be modulated by some other BM-derived cells including (but not limited to) RBCCs,
TASCs, DCs, TEMs and MDSCs. Mediated by SDF1, a chemokine induced by tumor-derived VEGF in activated perivascular myofibroblasts, RBCCs enhance
new capillary growth from a perivascular position [123]. TASCs colonize the tumor stroma and are thought to enhance tumor capillary sprouting in a paracrine
manner by inducing or increasing the expression angiogenic cytokines [122]. DCs might promote angiogenesis through different mechanisms: by stimulating
EC sprouting through the expression of angiogenic molecules and by differentiating into endothelial-like cells. Besides inhibiting the functional maturation
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ff DCs, VEGF is thought to be a major player in these processes [119]. TE
umor sites and promote angiogenesis in a paracrine manner [68]. MDSCs
nto the endothelial tube and differentiating into ECs [106].
.4. Endothelial progenitor cells in human tumors
The involvement of EPCs in the vascularization process
f human tumors has been investigated in some recent stud-
es as well. Peters et al. studied tumor samples from patients
ho developed malignancies after BM transplantation with
onor cells derived from individuals of the opposite sex.
y using FISH with sex chromosome-specific probes, these
uthors reported that the percentage of BM-derived ECs
n the tumors ranged from 1% (head and neck sarcoma)
o 12% (lymphoma) [76], which was closer to the num-
ers observed in spontaneous animal tumors than the zero
b
t
d
[monocytes that express the TIE2 receptor, are recruited to periendothelial
ute to tumor growth and angiogenesis by producing MMP9, incorporating
r extremely high numbers found when implanting tumor
ells. Recent studies have demonstrated the presence, based
n their CD133 immunoreactivity, of incorporated EPCs in
he walls of human tumor blood vessels as well [77–80].
ccordingly, CD133 mRNA expression in the PB of can-
er patients was shown to be an independent predictor for
verall survival in patients with bone metastases [81] and
or recurrence in colorectal cancer patients [82]. However,
ecause CD133 expression is continuously decreasing on
he cell surface of circulating EPCs and lost once EPCs
ifferentiate into more mature ECs in the endothelial tube
2,33,43], it seems obvious that based on CD133 staining, the
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ate of incorporated EPCs in cancer capillaries is inevitably
nderestimated.
Recently reported data also indicate that EPCs circulate
n increased numbers in the PB of patients with various types
f cancers. Elevated EPC levels have been reported in the PB
f patients with lung [80,83], hepatocellular [46,79], breast
25,84,85] and colorectal [86,87] cancers, as well as multiple
yeloma [23], myelofibrosis [88], non-Hodgkin’s lymphoma
77], AML [24] and malignant gliomas [89] (Table 2).
. Proangiogenic hematopoietic cells (Fig. 1)
Hematopoiesis has an evolutionarily conserved relation-
hip with vascular development [90]. HSCs adhere closely
o ECs at various sites in the embryo, including the yolk sac
nd the dorsal aorta [91,92]. In turn, yolk sac ECs can sup-
ort the proliferation of multipotent hematopoietic stem cells
93]. Furthermore, as mentioned above, HCs and ECs are
elieved to originate from a common precursor cell, known
s the hemangioblast [94,95]. Accordingly, in the adult, sub-
tantial evidence indicates that beside EPCs, hematopoietic
ineage cells also support the process of tumor vasculariza-
ion, although most of them are localized to periendothelial
umor sites.
Mast cells (MCs) participate in various angiogenesis-
ependent diseases/states including rheumatoid arthritis,
vulation, wound healing and tumor growth. Accordingly,
everal MC mediators are angiogenic and control EC prolifer-
tion and function. MCs express interleukin-8 (IL-8), MMPs,
asic FGF, TNF- and VEGF. Moreover, they can enhance
umor vascularization indirectly by producing MC-specific
erine proteases (MCP-4 and MCP-6) that activate pro-
MPs (reviewed in ref. [96]). MCs are also able to produce
istamine and heparin, which can stimulate EC sprouting
directly or indirectly by the stabilization of growth factors)
nd may have a role in the leakiness of immature tumor
apillaries. Finally, reduction of tumor MC density/function
as been shown to inhibit angiogenesis and, therefore, tumor
rowth [97,98].
Most cancers appear to be infiltrated by tumor-associated
acrophages (TAMs), which can comprise more than
0% of the total tumor mass. Depending on forms of
ctivation, macrophages can show two general types of
olarization, M1 and M2 (described in detail in ref. [99]).
lthough M1-polarized macrophages have the potential to
ill tumor cells, many observations indicate that TAMs more
ikely represent an M2-polarized macrophage population
xhibiting protumor functions, including the secretion of
ngiogenic molecules [99,100]. Indeed, in most human stud-
es, macrophage infiltration of the tumor was associated with
oor prognosis, and generally correlated with vascular den-
ity [101–103].
A heterogeneous population of cells sharing their differ-
ntiation pathway with TAMs is designated myeloid-derived
uppressor cells (MDSCs). MDSCs are myelomonocytic
r
w
U
tgy/Hematology 69 (2009) 108–124
ells lacking the markers of mature myeloid cells and
xpressing CD11b and Gr-1 in mice. They have been
eported to accumulate in tumor-bearing hosts and to suppress
-cell-mediated antitumor immune responses by diverse
echanisms [100,104,105]. Furthermore, when co-injected
ith tumor cells, CD11b+Gr-1+ cells promoted tumor vas-
ularization by producing MMP-9, and were also found to
irectly incorporate into tumor capillaries [106]. However,
he human equivalents of MDSCs are less well characterized,
lthough immunosuppressive granulocyte subpopulations
nd immature myeloid cells have been described in several
ancer types [107–109].
TIE2-expressing monocytes (TEMs, a subset of circu-
ating and tumor-infiltrating monocytes), identified by De
alma et al. [68], are recruited to periendothelial positions and
nhance tumor vascularization in a paracrine manner in mice.
hey are CD11b+/CD45+/TIE2+ cells, but do not express
EGFR2 or any established EC or pericyte-associated mark-
rs (e.g. CD31, CD34 or SMA and NG2). In subsequent
tudies, the same authors demonstrated that TEMs are specif-
cally recruited to spontaneously arising murine pancreatic
arcinomas and to human glioma xenografts [110]. The
urface-marker profile and angiogenic behavior of human
EMs were found to be reminiscent of those of previously
escribed murine TEMs [111].
In contrast to TAMs, most studies on infiltrating DCs
ave demonstrated that high DC density in tumors is associ-
ted with good prognosis and reduced incidence of recurrent
isease in various malignancies [112–114]. However, some
C subsets, such as CD123+/CD303+ plasmacytoid DCs or
mmature or incompletely matured DCs have been suggested
o mediate tolerance instead of immune activation [104,115].
t is also important to note that tumor-derived factors, such as
EGF and TGF-, can inhibit functional maturation of DCs
116,117] and that VEGF expression negatively correlated
ith DC density in tumors [112,116,118].
Recent results also suggest that different DC subtypes
xpress and release a wide range of pro- and antiangio-
enic molecules depending on their activation status and
ytokine milieu. A major subset of DCs, MHC II+/CD11c+
yeloid DCs, for example was shown to express the proan-
iogenic molecules VEGF, bFGF, TNF-, IL-6 and the
ntiangiogenic cytokines IL-10, IL-12, IL-18 and TSP-1
thrombospondin-1) as well. Similarly, depending on the
timulus, plasmacytoid DCs, the other major DC subtype,
an also release both angiogenic (TNF-, CXCL8) and
ngiosuppressive IFN- (interferon-) molecules (reviewed
n ref. [119]). Moreover, a novel DC subpopulation
CD11c+/CCR6+/MHC II+ DC precursors, tumor-associated
Cs, TADCs, Table 1) that supports tumor vascularization
as described recently by Conejo-Garcia et al. [120,121].
n their experiments, these authors found that -defensins
ecruited dendritic precursors through CCR6 into the tumor,
here VEGF-A transformed them into endothelial-like cells.
nlike TEMs, these cells mainly migrated to the endothelial
ubes, becoming true endothelial-like cells. All in all, DCs
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ight enhance tumor vascularization by two different but
ossibly interconnected mechanisms: by promoting endothe-
ial sprouting through the expression of angiogenic cytokines
nd by supporting vasculogenesis via trans-differentiation
nto endothelial-like cells (reviewed in ref. [119]).
Further proangiogenic HCs that have been directly impli-
ated in tumor vascularization include tumor-associated
tromal cells (TASCs) [122], recruited blood circulating cells
RBCCs) [123] and VEGFR1+ hematopoietic progenitors
65] (Table 1).
Tumor-associated stromal cells (TASCs) were described
y Udagawa et al. [122]. These CD45+/VEGFR2+ double
ositive cells have the ability to enhance tumor angiogene-
is, although are minimally recruited into the tumor capillary
alls. Instead, these authors suggested that TASCs might
ndirectly augment tumor vascularization in a paracrine man-
er by inducing or increasing the angiogenic molecules that
timulate in situ vessel formation (endothelial sprouting).
Like TEMs and TASCs, RBCCs [123] were shown to sup-
ort new blood vessel growth via secreting proangiogenic
actors from a perivascular position. RBCCs are positive for
D45, CD11b, CXCR4 and VEGFR1 but not for VEGFR2,
ndicating that they are recruited by VEGF and CXCL12 and
re predominantly hematopoietic in nature. It is also impor-
ant to note that Lyden et al. recently described VEGFR1+
ematopoietic progenitors that proliferate in the BM, mobi-
ize to the bloodstream along with VEGFR2+ EPCs, and
ncorporate into pericapillary connective tissue, thereby sta-
ilizing tumor vasculature [65]. More interestingly, these
ells appear to home in before the metastatic tumor cells
rrive to the target organ, promoting the metastatic process by
orming niches where cancer cells can locate and proliferate
124]. However, to what extent these VEGFR1+ progenitors
verlap with RBCCs remains to be elucidated.
The aforementioned studies together with Harraz et al.’s
125] suggestion that CD34-angioblasts are a subset of
D14+ monocytic cells, Rehman et al.’s [126] demonstra-
ion of the isolation of CACs from the monocyte/macrophage
raction of PB, and Yoder et al.’s [127] finding that CFU-ECs
xpressed colony-stimulating factor-1 receptor (CSF-1R) and
ctively phagocytosed Escherichia coli highlighted the abil-
ty of proangiogenic HCs to enhance tumor vascularization.
hese studies also demonstrated that hematopoietic and
ndothelial lineage cells share functional and phenotypical
eatures, including the expression of common metabolic and
urface molecules, as well as the capacity to shape vascular-
ike structures. However, these experiments with the cell
opulations growing in the above-described cell cultures con-
aining the PB mononuclear cell fraction have also led to some
ontroversy over whether CACs and CFU-ECs represent
PCs or in fact identify monocytes/macrophages. To clar-
fy the complex nomenclature and the relationships among
PC types to mononuclear cell subtypes, an elegant work-
ng hypothesis was suggested recently by Prater et al. [38].
ccording to the proposal of these authors, CACs represent
he largest population of cultured EPC types, comparable in
p
i
n
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ize to PB monocytes, which are hypothesized to belong to the
AC population. These authors also suggested that CD45+
roangiogenic HCs overlap with CFU-ECs to an undefined
egree and that ECFCs are included in the CEC population.
It is also important to note that beside the above described
roangiogenic HCs that are directly implicated in tumor vas-
ularization, other HC types such as polymorphonuclear cells
PMNs), NK cells and T and B lymphocytes may also par-
icipate in the vascularization process. Activated PMNs are
eported to secrete a number of angiogenic molecules includ-
ng MMPs, VEGF and IL-8. However, the PMN population
as demonstrated to be a source of endogenous angiogen-
sis inhibitors (such as angiostatin, IL-12-inducible protein
0, and IFN-) as well [5]. To make the picture more com-
lex, PMNs also secrete chemotactic factors to recruit other
MNs, monocytes, T cell subsets and immature DCs [5].
egarding lymphocytes, Qin et al. found that the primary
echanism of tumor rejection by CD8+ T cells in mouse mod-
ls was angiostasis mediated by IFN- [128]. On the other
and, production of VEGF by tumor-infiltrating T cells has
een described, which could play a role in tumor angiogen-
sis [129]. In cutaneous melanoma, we found a correlation
etween peritumoral microvessel density and the infiltration
y T cells [130]. In some animal models, a role of NK cells
s angiogenesis inhibitors via IL-12 and IFN- secretion has
een suggested [131]. Few data are available on the effect of
lymphocytes on tumor vascularity; in a transgenic mouse
odel, transfer of B cells from HPV16 mice into T and B
ell-deficient/HPV16 mice restored chronic inflammation in
remalignant skin and reinstated regulatory mechanisms nec-
ssary for angiogenesis [132]. Taken together, although all
hese cell types have been reported to express a wide reper-
oire of pro- and antiangiogenic factors, their “angiogenic
unction” has been poorly investigated and their exact role in
he blood supply of tumors remains unclear (reviewed in ref.
103]).
In summary, tumor-derived angiogenic factors do not
erely trigger the release of EPCs, but also enhance the
o-mobilization of proangiogenic HCs to the tumor vascu-
ar network and/or stroma. This co-recruitment of different
ineages may support capillary sprouting and stabilization of
mmature cancer capillaries through the release of additional
roangiogenic factors or by generating permissive conditions
n the tumor stroma that favor the survival and/or growth of
reexisting tumor vessels.
. Antiangiogenic and/or anticancer therapy via
PCs, proangiogenic HCs and CECs
One of the greatest hopes for the study of EPCs and, to
lesser extent, of proangiogenic HCs and CECs, is theirotential use in cancer therapy as cellular vehicles for deliver-
ng suicide genes, toxins or antiangiogenic molecules. These
ovel anticancer techniques, typically with the ex vivomanip-
lation of these cells, have been applied to transplantation
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odels and, to some extent, have reduced cancer progres-
ion. For example, Ferrari et al. transduced human EPCs with
retroviral vector expressing the herpes simplex virus thymi-
ine kinase (HSV-TK) transgene, and then injected these cells
ntravenously into sublethally irradiated mice bearing subcu-
aneous or intracranial tumors. Ganciclovir treatment resulted
n significant tumor regression in mice previously injected
y TK-expressing EPCs with no systemic toxicity [133]. In
similar study, unsorted murine BM cells were transduced
ith a retroviral vector to express truncated soluble VEGFR2
tsVEGFR2) together with green fluorescent protein (GFP) or
FP alone. The subsequent experiments have demonstrated
hat GFP-positive BM-derived cells contributed to tumor
apillaries and, when modified to express the angiogene-
is inhibitor tsVEGFR2, restricted tumor growth [134]. In
nother gene delivery approach, ex vivo expanded EPCs that
ere genetically modified with a suicide gene specifically
nd efficiently eradicated hypoxic lung metastases [135].
Differentiated endothelial cells have also been employed
or experimental tumor therapy. In a murine metastatic
elanoma model, the intravenous administration of genet-
cally modified CECs expressing a human IL-2 transgene
brogated the tumor metastases and prolonged survival of
he animals [136]. Similarly, co-injections of HSV-TK-
xpressing ECs and tumor cells reduced in vivo tumor growth
nd provided a statistically significant survival benefit in
xperimental animals [137].
Finally, the observation that proangiogenic HCs are
ble to support tumor growth and home to sites of active
ngiogenesis suggests that these cells may provide the
eans for selective gene delivery and targeted inhibition of
umor angiogenesis as well. Consistent with this hypothe-
is, De Palma et al. transduced TEMs with lentiviral vectors
xpressing genes from transcription-regulatory elements of
IE2/TEK gene and achieved a substantial inhibition of
ngiogenesis and slower tumor growth without systemic tox-
city by delivering a “suicide” gene [68].
Taken together, the use of the above cells in cancer ther-
py as cellular vehicles for delivering suicide genes, toxins or
nticancer/antiangiogenic agents opens new ways to hinder
umor growth. However, given the existence of alternative
ascularization mechanisms in cancer [4], the different EPC
nd CEC counts reported in various tumor models/cancer
ypes, the association of EPC levels with the histological
ype/stage of the tumor, and the unresolved question of
hether or not CECs are active participants in tumor vas-
ularization, the applicability of these cell populations as
Trojan horses” in anticancer therapy certainly needs further
nvestigation.
. EPCs and CECs: potential biomarkers of tumor
ngiogenesis?
The efficacy of conventional antitumor treatments (i.e.
hemo- and radiotherapy) is typically assessed by measuring
t
t
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heir direct effects on tumor size and/or survival. Because
ntiangiogenic drugs specifically target the tumor vascula-
ure, in case of these treatments, assessment of the above
arameters is an inadequate strategy and we need to be able to
valuate the biological effects of antiangiogenic drugs on the
umor capillaries independently of their general anticancer
ctivity.
The biomarkers used to measure the efficacy of thera-
eutic drugs of any type can be classified as either direct
r surrogate (indirect) in nature. In case of antiangiogenic
rugs, the direct biomarker is the actual capillary network in
he tumor, which is generally difficult to depict and quantify
138]. Consequently, reliable surrogate markers are needed
hat indirectly indicate the effect of antiangiogenic therapy on
umoral blood vessels and that can help to identify patients
esponsive to these therapies, recognize resistance and pre-
ict the efficacy of combinations that include antiangiogenic
rugs [139,140].
Although currently no single reliable biomarker is avail-
ble, encouraging results from different disciplines have been
eported.
One of the potential strategies is the measurement of
erum/plasma angiogenic cytokine and/or soluble growth
actor receptor levels in the blood and/or urine. For exam-
le, plasma concentrations of total VEGF and PlGF were
bserved to be significantly elevated in bevacizumab-treated
olon carcinoma patients [87]. In another clinical study
n patients with colorectal cancer, an elevation of plasma
EGF-A and bFGF was found following the first cycle of
TK787/ZK222584 (an angiogenesis inhibitor targeting all
nown VEGF receptor tyrosine kinases) treatment [141].
imilarly, a progressive increase of total VEGF levels after
nitiation of treatment with bevacizumab in renal cancer was
eported [142]. However, the use of cytokines as biomarkers
f angiogenesis is complicated by the release of angiogenic
rowth factors from platelets and there are several studies of
ngiogenic molecules as surrogate markers that have yielded
nconclusive evidence of their reliability [139].
Measuring the efficacy of antivascular therapy could also
e achieved by imaging the tumor capillaries themselves (i.e.
irect imaging by agents targeted at cytokines or receptors
nvolved in tumor vascularization) or investigating the result
f such treatments on the anatomic features and the blood sup-
ly of tumors (indirect imaging). Currently, almost all direct
echniques are available solely in murine models, whereas
ndirect techniques are typically used in clinical settings
138]. Accordingly, with the exceptions of a few recent stud-
es [143,144], experience with vascular imaging in human
tudies has been gained primarily by indirect techniques.
hese include measurements of contrast enhancement, blood
olume and oxygen saturation with computed tomography
CT), magnetic resonance imaging (MRI), positron emission
omography (PET) and single photon emission computed
omography (SPECT) (reviewed in ref. [138]).
Circulating EPC/CEC levels as surrogate markers of
ngiogenesis have also been investigated recently. Based
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n results from studies on murine tumor systems, there is
clear relationship between tumor burdens and EPC/CEC
ounts in the PB [145]. Moreover, circulating CEC and EPC
ounts have also been demonstrated to change with anti-
ancer/antiangiogenic treatments in preclinical models. For
xample, as mentioned above, Bertolini et al. found that when
umorous mice are treated with MTD chemotherapy, there
s a marked elevation in EPC counts in the PB during the
rug-free break periods. This tendency was not observed
hen the same drug was administered metronomically. In
act, the opposite was reported; namely, almost total sup-
ression of EPC and CEC numbers and viabilities [73].
n other murine studies, treatment of tumor-bearing mice
ith vascular disrupting agents (VDAs) led to an abrupt
elease of EPCs, which incorporated into the capillaries of
iable peripheral tumor areas (tumor rims) that characteris-
ically survive after such treatment. Suppression of this EPC
obilization by antiangiogenic agents resulted in marked
eductions in tumor rim size and blood flow as well [146].
oreover, endostatin decreased EPC numbers in the PB
long with tumor regression [147,148], and VEGFR2 tar-
eting caused a dose-dependent decrease in EPC counts that
aralleled the anticancer activity of the experimental agent
149].
More importantly, techniques for EPC/CEC detection
nd counting have been tested in the clinics [9], and stud-
es have been undertaken measuring the numbers of these
ells in cancer patients treated with antiangiogenic thera-
ies. Particularly encouraging in this regard is a phase 1 trial
n which bevacizumab, an anti-VEGF antibody, decreased
umor perfusion, vascular volume, microvascular density,
nterstitial fluid pressure and the number of EPCs and
D31bright/CD45− viable CECs in rectal carcinoma patients
86,87]. Interestingly, in a vigorously criticized [150] subse-
uent study [151], the investigators of the above trial were
nable to detect significant changes in CD146+ CEC levels
uring VEGF blockade.
Subsequent studies have yielded promising but sometimes
nconsistent results likely dependent on the type and stage
f the malignant disease and, moreover, on the therapeu-
ic regime and enumeration technique chosen. In a phase
/II study of patients with imatinib-resistant metastatic GIST,
he authors investigated plasma and PB cellular biomarkers
or sunitinib malate, a multitargeted tyrosine kinase inhibitor
ith activity against VEGFR1, VEGFR2, VEGFR3, PDGF
eceptor, KIT, and FLT-3 (FMS-like tyrosine kinase 3) and
ound that changes in CECs, but not the plasma markers
VEGF and soluble VEGFR2), differed between the patients
ith clinical benefit and those with progressive disease [27].
phase II prospective study of low-dose cyclophosphamide
iven continuously (i.e. metronomically) in combination with
elecoxib in adult patients with relapsed or refractory aggres-
ive non-Hodgkin’s lymphoma has recently demonstrated
hat CECs and EPCs declined and remained low in respon-
ers, whereas plasma VEGF tended to decline in responding
atients but increase in nonresponders [152]. Similarly, CEC
o
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nd EPC counts were found to be correlated with disease
ctivity (i.e. levels of serum M protein and 2 microglobu-
in) and response to thalidomide therapy in multiple myeloma
23]. Moreover, in a phase I trial of pediatric patients with
efractory solid tumors, although not statistically signifi-
antly, CECs tended to increase with bevacizumab therapy
153]. There are other studies, however, in which no corre-
ation between circulating levels of CECs/EPCs and tumor
rogression/response was found. For example, in a phase I
tudy of patients with refractory solid malignancies, the dif-
erences in the numbers of CECs and EPCs between patients
nd controls were not statistically significant and, further-
ore, no changes in the levels of these cells were observed
uring low-dose cyclophosphamide and celecoxib or low-
ose etoposide and celecoxib therapy [154]. Similarly, in a
hase I study of the protein kinase C inhibitor enzastaurin in
ombination with gemcitabine and cisplatin in patients with
dvanced tumors, the single-agent enzastaurin had no effect
n any of the angiogenesis biomarkers analyzed (circulating
EC levels and mRNA expression of CD133 and CD146 in
he PB).
As antivascular therapies for cancer become increasingly
ntegrated into routine oncology care, there is an urgent need
or the proper selection of the patients most likely to benefit
rom these treatments. The results described above are par-
icularly significant in this regard, as they may establish the
ole of EPC/CEC quantification not only in the evaluation
f the efficacy of antiangiogenic treatments, but also in the
efinition of optimal biologic dose ranges as well. More stud-
es, however, are needed to expand and validate these initial
ndings.
. Conclusions
The key role of the vasculature during tumor progression
s unquestionable. Moreover, it is becoming clear that BM-
erived EPCs and proangiogenic HCs are involved in the
rocess of neovascularization and that CEC and EPC levels
an be biomarkers of targeted anticancer/antivascular thera-
ies. Recent reports also suggest that BM-derived circulating
ells can be used as cellular vehicles to deliver anticancer
gents. Questions remain, however, regarding the precise
unctional and phenotypic nature of these circulating cells
nd whether certain HCs will have any value as biomarkers as
ell. Hence, further studies and consensus is required regard-
ng the phenotype and enumeration approaches of these cell
opulations in order to help define their optimal role in clin-
cal oncology.
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